Ep190: Neil Kumar on Building a Rare Disease Drug Company

Episode Summary

Executive Summary: Neil Kumar explains how BridgeBio built a rare-disease biotech model around a hub-and-spoke portfolio, using centralized infrastructure, diversified assets, and disciplined capital allocation to fund biologically compelling programs that traditional venture overlooked. The conversation centers on acoramidis (Atrubi) in ATTR cardiomyopathy, the painful part-A setback, the debt-fueled endurance that saved the company, and recent positive readouts that could make BridgeBio a multi-product, cash-generating biotech.

Main Topics: Origin story and scientific formation (Priority: 4/5): Kumar traces his path from Boston and Rochester to Andover, Stanford, and MIT, emphasizing a lifelong attraction to chemistry, quantitative thinking, and the chemistry-biology interface that shaped his approach to biotech. Why BridgeBio was founded (Priority: 5/5): He explains that rare-disease assets were scientifically attractive but did not fit the venture model of the time because they were small, non-platform, and often too capital-intensive for standalone financing. Hub-and-spoke operating model (Priority: 5/5): BridgeBio’s structure combines centralized R&D infrastructure, decentralized disease-focused teams, and portfolio diversification so each program gets specialist attention while fixed costs and capital are shared. Acoramidis/ATTR cardiomyopathy thesis (Priority: 5/5): The transcript details the biology behind TTR stabilization, the rescue-mutation insight, and why Kumar believed a more potent stabilizer could outperform earlier therapies in ATTR cardiomyopathy. Clinical setback and turnaround (Priority: 5/5): Part A of the phase 3 trial missed on six-minute walk distance because standard of care changed and the placebo arm did not decline as expected; later Part B showed meaningful benefit on hard outcomes, validating the drug. Capital strategy and debt financing (Priority: 4/5): BridgeBio raised substantial debt ahead of approval, which preserved trial continuity and diversified development, but also spooked equity investors and depressed the stock after the interim miss. Pipeline diversification and future outlook (Priority: 5/5): Recent positive readouts in limb-girdle muscular dystrophy type 2I and ADH1 suggest BridgeBio may become a rare, independent biotech with multiple approved products and sustainable cash flow.

Key Arguments: Rare-disease drug development needs a different financing and operating model because many biologically strong programs are too small or too non-platform to attract conventional venture funding. A centralized hub-and-spoke model reduces duplication, preserves scientific focus in each disease, and allows capital and infrastructure to be redeployed across programs. Diversification in BridgeBio is not about correlated bets; the assets are biologically distinct, which lowers portfolio-wide risk versus platform-heavy models. Acoramidis was compelling because the biology of ATTR cardiomyopathy was unusually well understood, and stronger TTR stabilization should translate into better outcomes. The negative interim phase 3 readout was driven by changing standard of care and an unexpectedly stable placebo arm, not failure of the drug mechanism. Debt financing, though unpopular with biotech equity investors, was essential to keep the company alive long enough to read out the full phase 3 data and support other pipeline programs. BridgeBio’s objective is to help as many patients as possible with best- or first-in-class medicines, not to maximize value from a single asset. Positive readouts in LGMD2I and ADH1 support the thesis that the platform can repeatedly generate clinically meaningful medicines across different rare diseases.

Data Points: BridgeBio founding year: 2015 - Kumar says the company began with acoramidis as one of the initial candidate molecules. Acoramidis third-quarter revenue: $108 million - Mentioned as blockbuster sales in its third quarter on the market. ATTR market size estimate: $15 billion to $20 billion - Kumar says analysts estimate the market at $15B and he believes it could reach $20B. Peak market share target: 30% to 35% - His view of BridgeBio’s likely peak penetration for acoramidis. Acoramidis development spend: well under $300 million - He says total discovery-to-development spend was below this level. Debt raised: well over $1 billion - BridgeBio raised this amount before and around the part-A setback, crucial for survival. First funding round: $7 million - Initial check came from tech-oriented high-net-worth investors. First approved drug before acoramidis: Nulibri (molybdenum cofactor deficiency type A) - Kumar notes it was approved but later sold during the downturn. Acoramidis stabilization: 90%+ stabilization - The drug was designed to outperform earlier TTR stabilizers by more fully stabilizing the tetramer. Earlier TTR stabilizer (Tafamidis): ~35% stabilizer at 20 mg - Used as a comparison point for why early data were viewed as middling. Ionis inotersen knockdown: ~70% knockdown - Kumar compares knockdown potency to stabilization potency in ATTR biology. Alnylam knockdown: 84% mean max knockdown - Referenced as another proof point that higher target suppression improved outcomes. Part B hospitalization/death reduction: 42% - Reported for acoramidis at 30 months on combined hospitalization and death. Hospitalization reduction: 50% - Part B showed a 50% reduction in hospitalization. LGMD2I patient population: about 7,000 patients in the U.S. and EU - Kumar describes the target population for the muscular dystrophy program. Muscle damage reduction in LGMD2I: 80% to 90% - CK levels fell dramatically in the recent readout. ADH1 normalization rate: over 70% of patients - Therapy normalized urine and serum calcium in a majority of treated patients. Standard-of-care normalization in ADH1: less than 5% - Used as the comparator for the calcium-sensing receptor program. LGMD2I functional readout: statistically significant improvement across all functional endpoints - Ambulation and breathing improved, while all placebo patients declined.

Pivotal Quotes: "I typically am only in a bad mood when nothing is working." — Neil Kumar: Early in the interview, describing his emotional state as CEO after recent company success. "The issue was each one of those programs alone were not really financeable in at that time the venture construct." — Neil Kumar: Explaining why BridgeBio needed a different business model for rare disease assets. "Don't fight the markets." — Neil Kumar: One of his three pieces of advice to his younger self and young scientific entrepreneurs.

Implications: BridgeBio’s path suggests rare-disease biotech can be built as a durable portfolio business, not just single-asset speculation. If the model keeps working, it could broaden funding for underappreciated genetic diseases and create a template for efficient, diversified drug creation.